INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
Oct. 12, 2018 |
Aug. 20, 2018 |
Jul. 28, 2016 |
Jan. 26, 2016 |
Mar. 31, 2019 |
Mar. 31, 2018 |
Dec. 31, 2016 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Intellectual property fees | $ 55,648 | ||||||||
| Description for right to purchase perpetual rights | North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life. | ||||||||
| Amortization expenses | $ 0 | $ 1,963 | |||||||
| Impairment loss | 250,000 | ||||||||
| Carrying value | 0 | $ 0 | |||||||
| Therakine, Ltd. [Member] | |||||||||
| License cost | $ 2,750,000 | ||||||||
| Aggregate purchase price, value | $ 250,000 | $ 250,000 | $ 250,000 | ||||||
| Escrow deposit | $ 75,000 | $ 75,000 | |||||||
| Patent acquired | $ 15,200 | ||||||||
| Intellectual property description | approximately 11 patents pending and 1 issued patent. | ||||||||
| Therakine, Ltd. [Member] | Minimum [Member] | |||||||||
| Milestone payments and royalties | 5.00% | ||||||||
| Therakine, Ltd. [Member] | Maximum [Member] | |||||||||
| Milestone payments and royalties | 12.00% | ||||||||
| Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member] | |||||||||
| Aggregate purchase price, value | $ 236,000 | ||||||||
| Aggregate purchase price, Shares | 10,000 | ||||||||
| Naltrexone Implant Formulation [Member] | New Zealand from Trinity Compound Solutions [Member] | |||||||||
| Aggregate purchase price, value | $ 236,000 | ||||||||
| Aggregate purchase price, Shares | 20,000 | ||||||||